Nevertheless, for mCRPC the clinical benefit of using [177Lu]Lu-RM2 is limited to patients who have high expression of GRPr and experienced xerostomia as a dose-limiting event after PSMA-targeted RLT. The gene discussed is FOLH1; the disease is xerostomia.